TABLE 4.
Details of patients with injection site bleeding (part B)
| P1 | P2 | P3 | P4 | P5 | P6 | |
|---|---|---|---|---|---|---|
| Baseline characteristics | ||||||
| Age, years | 58 | 57 | 34 | 57 | 50 | 63 |
| Haemophilia | HA | HA | HA | HA | HB | HA |
| Severity | Severe | severe | severe | moderate | mild | Severe |
| Inhibitor | Never | never | never | never | never | Never |
| Body weight, kg | 92 | 72 | 68 | 95 | 95 | 83 |
| Regular prophylaxis | y | y | Y | n | n | N |
| Drug | SHL | SHL | SHL | – | – | SHL |
| Last factor dose administered before 1st/2nd vaccination | ||||||
| Dose, IU/kg | 22/22 | 28/28 | 44/44 | 0/0 | 0/0 | 36/36 |
| Time, h | 17/17 | 16/13 | 2/3 | – | – | 2/72 |
| In addition to routine prophylaxis | y/y | y/y | n/n | – | – | y/n |
| Bleeds after 1st/2nd vaccination | ||||||
| Local Hematoma | y/y | y/n | y/n | y/n | n/y | n/y |
| Diameter, cm | 5/5 | 1/‐ | 7/‐ | 3/‐ | ‐/3 | ‐/6 |
| Pain score, VAS | 1/2 | 1/‐ | 2/‐ | 0/‐ | ‐/6 | ‐/0 |
| Doses for treatment, n | 1/1 | 0/‐ | 0/‐ | 0/‐ | ‐/0 | ‐/1 |
Abbreviations: n, no; P, patient; SHL, standard half‐life factor concentrate; VAS, visual analogue scale; y, yes.